Table 1.

Demographic characteristics and comorbidities for 21 individuals with MIS-C who had received a COVID-19 vaccine

	Total (n=21)	Laboratory evidence of SARS-CoV-2 infection (n=15)	No laboratory evidence of SARS-CoV-2 infection (n=6)
Age at time of MIS-C onset, years
12–15	10 (48%)	7 (47%)	3 (50%)
16–17	5 (24%)	5 (33%)	0 (0%)
18–20	6 (29%)	3 (20%)	3 (50%)
Sex
Female	8 (38%)	5 (33%)	3 (50%)
Male	13 (62%)	10 (67%)	3 (50%)
Race or ethnicity
White, non-Hispanic	8 (38%)	4 (27%)	4 (67%)
Hispanic	5 (24%)	4 (27%)	1 (17%)
Black, non-Hispanic	3 (14%)	3 (20%)	0 (0%)
Asian or Pacific Islander, non-Hispanic	3 (14%)	2 (13%)	1 (17%)
Other race, non-Hispanic*	2 (10%)	2 (13%)	0 (0%)
Comorbidities
Asthma	7 (33%)	6 (40%)	1 (17%)
Obesity	3 (14%)	2 (13%)	1 (17%)
Seizure disorder	1 (5%)	0 (0%)	1 (17%)

Data are n (%). MIS-C=multisystem inflammatory syndrome in children.

^*This category includes one person with multiple races and one with unknown race.